Authors and Disclosures
Eric Barnett1*, Kathleen G Palma1, Bert Clayton1 and Timothy Ballard2
1 Piedmont Pharmaceuticals, Greensboro, NC, USA. 2 En-Cas Analytical Laboratories, Winston-Salem, NC, USA
Competing interests
Piedmont Pharmaceuticals sponsored the study. Eric Barnett (EB) and Bert Clayton (BC) are employees of Piedmont Pharmaceuticals, the company that developed the non-pesticidal human head lice treatment composed of Isopropyl myristate/cyclomethicone D5 discussed in this paper. Kathleen Palma (KP) is a paid consultant of Piedmont Pharmaceuticals. This solution is marketed as Full Marks™ Solution by Reckitt Benckiser in certain European countries, Australia and Russia; as Resultz® by Medical Futures in Canada, Takeda in Belgium, and Lapidot in Israel. Tim Ballard (TB) of En-Cas Analytical Laboratories was paid on a fee for service basis to conduct the laboratory work, and does not have a competing interest.
*Corresponding author
ebarnett@piedmontpharma.com